FIBROBIOLOGICS INC (FBLG) Stock News
NASDAQ:FBLG - Nasdaq - US31573L1052 - Common Stock - Currency: USD
FBLG Latest News, Press Relases and Analysis
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+...
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are...
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third quarter of 2025
FibroBiologics Announces $25 Million Financing
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (
FibroBiologics Presents at the ThymUS 2025 Meeting
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+...
FibroBiologics Presenting at the ThymUS 2025 Meeting
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+...
FibroBiologics Presenting at the ThymUS 2025 Meeting
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (
FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology...
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
Located in Houston, Texas, the new facility allows FibroBiologics to expand its research and development efforts utilizing fibroblast-based technology
FibroBiologics gibt wissenschaftlicher Fortschritte bei der Reparatur von Hirngewebe bekannt
HOUSTON, April 03, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (im Folgenden kurz „FibroBiologics“), ein im klinischen Stadium tätiges...
FibroBiologics annonce des progrès scientifiques suite à la confirmation des résultats relatifs à la réparation de tissus cérébraux
HOUSTON, 03 avr. 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq : FBLG), ou « FibroBiologics », une société de biotechnologie au stade clinique...
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after...
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
FibroBiologics Announces 2025 Annual Meeting of Stockholders
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+...
FibroBiologics Announces 2025 Annual Meeting of Stockholders
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+...
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Life Sciences Investor Forum Agenda Announced for March 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
フィブロバイオロジックス (FibroBiologics)、線維芽細胞ベースの治療薬を用いたミトコンドリア活性の調節に関する新規アプローチで特許申請
この革新的な手法は、ミトコンドリアの機能異常が原因で起こる慢性疾患の新たな治療法につながる可能性が期待されている。 ヒューストン発 , March 05, 2025 (GLOBE NEWSWIRE) --...
FibroBiologics meldet Patent für neuartigen Ansatz zur Modulation mitochondrialer Aktivität mithilfe von auf Fibroblasten basierten Therapeutika an
Diese innovative Methode hat das Potenzial, neue Behandlungsmöglichkeiten für chronische Erkrankungen zu erschließen, die durch mitochondriale...
FibroBiologics dépose une demande de brevet pour une nouvelle approche visant à moduler l’activité mitochondriale à l’aide de produits thérapeutiques à base de fibroblastes
Cette nouvelle méthode pourrait ouvrir la voie vers de nouvelles options thérapeutiques ciblées sur des maladies chroniques causées par un...
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation. HOUSTON, March 04,...
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic
Master cell bank to be used in manufacturing of CYWC628 drug product to support upcoming clinical trial for diabetic foot ulcers...
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic
Master cell bank to be used in manufacturing of CYWC628 drug product to support upcoming clinical trial for diabetic foot ulcers
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
FibroBiologics to also present at the BIO CEO & Investor Conference...
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
FibroBiologics to also present at the BIO CEO & Investor Conference
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (
